IL222356A0 - Substituted 2,3-dihydroimidazo [1,2-c]quinazoline-containing combinations - Google Patents

Substituted 2,3-dihydroimidazo [1,2-c]quinazoline-containing combinations

Info

Publication number
IL222356A0
IL222356A0 IL222356A IL22235612A IL222356A0 IL 222356 A0 IL222356 A0 IL 222356A0 IL 222356 A IL222356 A IL 222356A IL 22235612 A IL22235612 A IL 22235612A IL 222356 A0 IL222356 A0 IL 222356A0
Authority
IL
Israel
Prior art keywords
dihydroimidazo
quinazoline
substituted
containing combinations
combinations
Prior art date
Application number
IL222356A
Other languages
English (en)
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44144895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL222356(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of IL222356A0 publication Critical patent/IL222356A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL222356A 2010-04-16 2012-10-11 Substituted 2,3-dihydroimidazo [1,2-c]quinazoline-containing combinations IL222356A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (1)

Publication Number Publication Date
IL222356A0 true IL222356A0 (en) 2012-12-31

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
IL222356A IL222356A0 (en) 2010-04-16 2012-10-11 Substituted 2,3-dihydroimidazo [1,2-c]quinazoline-containing combinations

Country Status (24)

Country Link
US (1) US20130184270A1 (enExample)
EP (1) EP2558126A2 (enExample)
JP (1) JP5886271B2 (enExample)
KR (1) KR20130098155A (enExample)
CN (1) CN102958540B (enExample)
AU (1) AU2011240003A1 (enExample)
BR (1) BR112012026480A2 (enExample)
CA (1) CA2796253A1 (enExample)
CL (1) CL2012002887A1 (enExample)
CO (1) CO6620036A2 (enExample)
CR (1) CR20120524A (enExample)
CU (1) CU20120150A7 (enExample)
DO (1) DOP2012000269A (enExample)
EA (1) EA201201414A8 (enExample)
EC (1) ECSP12012261A (enExample)
IL (1) IL222356A0 (enExample)
MA (1) MA34158B1 (enExample)
MX (1) MX2012012064A (enExample)
PE (1) PE20130191A1 (enExample)
PH (1) PH12012502069A1 (enExample)
SG (1) SG184550A1 (enExample)
TN (1) TN2012000493A1 (enExample)
WO (1) WO2011128407A2 (enExample)
ZA (1) ZA201208616B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
MX2015014171A (es) 2013-04-08 2015-12-16 Bayer Pharma AG Uso de 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas.
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
CN107683138A (zh) * 2015-03-09 2018-02-09 拜耳制药股份公司 取代的2,3‑二氢咪唑并[1,2‑c]喹唑啉类化合物的用途
EA201791974A1 (ru) * 2015-03-09 2018-05-31 Байер Фарма Акциенгезельшафт Комбинации, содержащие замещенный 2,3-дигидроимидазо[1,2-с]хиназолин
WO2017153220A1 (en) * 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
CA3068324A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag Combination of a pi3k-inhibitor with an androgen receptor antagonist
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004037875B4 (de) 2004-08-04 2008-05-08 Siemens Ag Sensorvorrichtung, Verfahren und Vorrichtung zum Überwachen einer Sensorvorrichtung
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1912636B1 (en) 2005-07-21 2014-06-25 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2291350A4 (en) * 2008-04-14 2012-09-19 Ardea Biosciences Inc COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Also Published As

Publication number Publication date
CO6620036A2 (es) 2013-02-15
ECSP12012261A (es) 2012-11-30
DOP2012000269A (es) 2012-12-15
CN102958540B (zh) 2015-09-02
SG184550A1 (en) 2012-11-29
WO2011128407A3 (en) 2012-02-23
US20130184270A1 (en) 2013-07-18
BR112012026480A2 (pt) 2016-08-16
MX2012012064A (es) 2012-12-17
JP2013525293A (ja) 2013-06-20
CN102958540A (zh) 2013-03-06
CU20120150A7 (es) 2013-02-26
EA201201414A8 (ru) 2013-12-30
AU2011240003A1 (en) 2012-11-08
ZA201208616B (en) 2015-08-26
MA34158B1 (fr) 2013-04-03
PE20130191A1 (es) 2013-02-21
KR20130098155A (ko) 2013-09-04
TN2012000493A1 (en) 2014-04-01
JP5886271B2 (ja) 2016-03-16
PH12012502069A1 (en) 2013-02-04
HK1182937A1 (en) 2013-12-13
CR20120524A (es) 2013-01-09
CA2796253A1 (en) 2011-10-20
EA201201414A1 (ru) 2013-04-30
WO2011128407A2 (en) 2011-10-20
EP2558126A2 (en) 2013-02-20
WO2011128407A9 (en) 2011-12-22
CL2012002887A1 (es) 2013-01-18

Similar Documents

Publication Publication Date Title
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
ZA201208616B (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
SG11201401342VA (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
AP2013007147A0 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
EP2619203A4 (en) TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND APPLICATIONS THEREOF
ZA201205788B (en) 1,2,4-triazine-4-amine derivatives
IL234485A (en) Compounds based on imidazo [2,1 – b] pyridazine
SI2507235T1 (sl) Triazolopirimidini
ZA201206630B (en) Hetaryl-[1,8]naphthyridine derivatives
IL229993A (en) 8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
AU334279S (en) Toy block
EP2581371A4 (en) PYRROLYL-SUBSTITUTED DIHYDROINDOL-2-ON DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
AU334278S (en) Toy block
IL221479A0 (en) Triazolo [4,5-b] pyridin derivatives
PL2572696T3 (pl) Inteligentna apteczka pierwszej pomocy
ZA201302112B (en) 1,4-oxazepane derivatives
PL2469107T3 (pl) Tuleja ślizgowa
TWI561274B (en) The pacemaker
HK1196363A (en) 5,7-substituted-imidazo[1,2-c]pyrimidines
AU2010901109A0 (en) Adjustable, multi-purpose plus
GB201020160D0 (en) The club
HK1176060A (en) Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
AU2010904564A0 (en) Build ball
AU2010903003A0 (en) Sequenced vaso-stimulii therapy
GB201019374D0 (en) Pet-waste kit